The global network point-of-care glucose testing market size is expected to reach USD 1.79 billion by 2030, registering a CAGR of 4.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increasing demand for safe and accurate remote patient monitoring options and the need for data-based treatment regimens are major factors driving the market. The integration of advanced technologies including Bluetooth Low Energy (BLE) and Infrared is expected to fuel the market growth in the upcoming years.
Network Point-of-Care Glucose Testing Market Report Highlights
- Network point-of-care devices were in high demand during the first and second wave of COVID-19 owing to their advantage of remote patient monitoring
- Based on product, the Accu-Chek Inform II segment dominated the market and accounted for a revenue share of 48.4% in 2023 and is expected to expand at a lucrative growth rate during the forecast period
- North America dominated the market with a revenue share of 40.7% in 2023 and is predicted to maintain its lead over the forecast period owing to the factors such as the presence of major players and high adoption rate
For More Details or Sample Copy please visit link @: Network Point-of-Care Glucose Testing Market Report
Expanding patient base in Asia Pacific and the Middle East and the high demand for advanced diabetes management systems are creating significant growth opportunities in these regions. These regions also include some of the highly preferred destinations for medical tourism. Increasing demand for world-class healthcare services and rising adoption of advanced technology are some of the factors boosting the market growth in these regions.
Network point-of-care glucose meters were extensively used in COVID-19 care. This enabled doctors to remotely observe glucose levels with minimal risk of infection. In addition, a large amount of data is still being used to customize treatment plans for diabetic COVID-19 patients. Preference for telemedicine and trends of home healthcare settings for chronic patients are some of the factors expected to expand the applications of network-based point-of-care devices.
List of major companies in the Network Point-of-Care Glucose Testing Market
- Abbott, LLC
- Nova Biomedical
- Danaher
- Hoffmann-La Roche Ltd.
- Ascensia Diabetes Care Holdings AG
- Prodigy Diabetes Care, LLC
- Nipro Corporation Japan
- ACON Laboratories, Inc.
For Customized reports or Special Pricing please visit @: Network Point-of-Care Glucose Testing Market Analysis Report
We have segmented the global network point-of-care glucose testing market on the basis of on product and region.
Research Methodology
We employ a comprehensive and iterative research methodology focused on minimizing deviance in order to provide the most accurate estimates and forecasts possible. We utilize a combination of bottom-up and top-down approaches for segmenting and estimating quantitative aspects of the market. Data is continuously filtered to ensure that only validated and authenticated sources are considered. In addition, data is also mined from a host of reports in our repository, as well as a number of reputed paid databases. Our market estimates and forecasts are derived through simulation models. A unique model is created and customized for each study. Gathered information for market dynamics, technology landscape, application development, and pricing trends are fed into the model and analyzed simultaneously.
About Grand View Research
Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S. based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.
Contact:
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll-Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: https://www.grandviewresearch.com
#HealthcareTech #PointOfCareTesting #GlucoseMonitoring #NetworkedHealthcare #DiabetesManagement #MedicalDevices #WearableTech #WirelessMonitoring #PatientCare #HealthTechInnovation #BloodSugarTesting #RemoteMonitoring #ConnectedHealthcare #DiagnosticsMarket #MedicalInnovation
Wearable biosensors for glucose monitoring specially, Continuous glucose monitoring devices have come a long way since the introduction of first and second generation of sensors.
The trend continues as there is more than ever increasing requirement for self-monitoring equipment and development of appropriate glucose biosensors to congregate the demands of the patients afflicted with this extremely rampant disorder.Our brief analysis provides intuitive insights pertaining to existing FDA cleared CGM devices and potential future technology developments by key industry leaders like (Abbott, Medtronic, Dexcom) along with emerging players in domain, bringing constructive improvement in diabetes management/care.For More Details @ https://www.iebrain.com/wp-content/uploads/2019/05/BIOSENSORS-FOR-GLUCOSE-MONITORING.pdf?
The rising prevalence of diabetes has increased the focus on the development and adoption of better solutions for diabetes care.
Also, advancements in technologies have ensured the introduction of highly flexible solutions in the market.
These are the major factors driving the growth of the global digital diabetes management market.
The increasing adoption of cloud-based enterprise solutions and the growing use of connected devices and apps are some of the other major factors supporting market growth.
Digital diabetes management solutions are smartphone-connected diabetes management devices and software platforms used by patients suffering from Type 1, Type 2, and gestational diabetes.
This study involved the extensive use of both primary and secondary sources.
At first glance, Amanda Rosengren looks like any other teenager.
She might seem fixated on her smartphone, but Amanda is doing something far more important than scrolling through her social media feeds.
Amanda has type one diabetes, and her phone — alongside a device containing a tiny wire created by Sandvik — help monitor her glucose levels without the need for daily testing.
Amanda received her diagnosis aged four, and her diabetes soon began to put pressure on her family’s life.
The sensor is among the most critical parts of the CGM, and its size is thinner than that of a needle.
Alongside the CGM, Amanda also has an insulin pump attached to her stomach, which automatically delivers the right dose of insulin according to the measurements the app recommends.
